Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.04. | Glenmark announces recall of high blood pressure medication in US | 69 | Pharmaceutical Technology | ||
14.04. | Glenmark recalls 6,528 bottles of blood pressure drug in US | 403 | ZEE Business | ||
12.04. | NTPC, Glenmark Pharma among 5 stocks with long buildup | 101 | Times of India | ||
10.04. | Lupin, Glenmark recall drugs in US market: USFDA | 134 | ZEE Business | ||
05.04. | Glenmark Pharmaceuticals Ltd up for five straight sessions | 48 | capitalmarket.com | ||
11.03. | Glenmark Pharmaceuticals Ltd gains for third straight session | 2 | capitalmarket.com | ||
23.02. | F&O stocks: Trent, Glenmark Pharma among 5 stocks with short buildup | 2 | Times of India | ||
20.02. | India's Glenmark Pharma could see better operating margins, says HSBC; hikes PT | 3 | Reuters | ||
20.02. | Hot Stocks: Brokerage view on Kotak Mahindra, Glenmark Pharma, Biocon and RIL | 4 | Times of India | ||
16.02. | India's Glenmark Pharma set for best 2-day gain in 3 yrs on upbeat results, forecast | 1 | Reuters | ||
16.02. | BPCL, Glenmark Pharma among 5 stocks with long buildup | 2 | Times of India | ||
15.02. | Glenmark Pharma reports net loss of Rs 331 cr in Q3 FY24 | 2 | capitalmarket.com | ||
15.02. | Glenmark Pharma trades higher despite pharma firm reports loss in December quarter | 2 | ZEE Business | ||
14.02. | Glenmark Q3 Results: Co reports net loss of Rs 351 cr on lower domestic sales | 2 | Times of India | ||
14.02. | Glenmark Q3 results: Company reports net loss of Rs 351 crore on lower domestic sales | 2 | ZEE Business | ||
13.02. | Glenmark Pharmaceuticals Ltd drops for fifth straight session | 2 | capitalmarket.com | ||
31.01. | Glenmark Pharma hits 52-week high on forming alliance to develop cancer drug | 2 | capitalmarket.com | ||
25.01. | Glenmark bags subcutaneous checkpoint inhibitor, moving to turf targeted by Big Pharma | 2 | FierceBiotech | ||
25.01. | Glenmark Pharmaceuticals Ltd: Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World | 280 | PR Newswire | Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. Jiangsu Alphamab... ► Artikel lesen | |
25.01. | Glenmark licenses cancer drug from China's Alphamab, 3D Med | 4 | pharmaphorum |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SINOPHARM | 2,615 | +1,28 % | SINOPHARM (01099): 2023 SUSTAINABILITY REPORT | ||
CSPC PHARMA | 0,772 | +2,71 % | CSPC Pharmaceutical Group-Aktie kann Vortagsniveau nicht halten (0,686 €) | Im Minus liegt zur Stunde die Aktie der CSPC Pharmaceutical Group . Das Wertpapier kostete zuletzt 0,69 Euro. An der Börse liegt die CSPC Pharmaceutical Group-Aktie aktuell im Minus. Die Aktie verbilligte... ► Artikel lesen | |
WUXI BIOLOGICS | 1,650 | +1,07 % | WUXI BIO (02269): NEXT DAY DISCLOSURE RETURN | ||
SHANGHAI FOSUN PHARMACEUTICAL | 1,470 | +0,14 % | FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL FOR DRUG REGISTRATION OF A SUBSIDIARY | ||
DR REDDYS | 68,50 | -0,72 % | Dr. Reddy's Recalls Sapropterin Dihydrochloride Powder For Oral Solution | NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level.According to the U.S. Food and... ► Artikel lesen | |
GEDEON RICHTER | 22,800 | -3,55 % | Aktien Osteuropa Schluss: Uneinheitlich ins Wochenende | PRAG/BUDAPEST/WARSCHAU (dpa-AFX) - Die wichtigsten osteuropäischen Aktienmärkte haben sich am Freitag in unterschiedliche Richtungen entwickelt. Während Budapest deutliche Verluste verbuchte, waren... ► Artikel lesen | |
ASPEN PHARMACARE | 10,600 | -1,85 % | ASPEN PHARMACARE HOLDINGS LIMITED - Completion of two Transactions with Sandoz | ||
LUYE PHARMA | 0,318 | 0,00 % | LUYE PHARMA (02186): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 | ||
SHANGHAI PHARMACEUTICALS | 1,330 | 0,00 % | SH PHARMA (02607): 2023 SUSTAINABILITY REPORT & ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | ||
SIHUAN PHARMACEUTICAL HOLDINGS GROUP | 0,052 | -22,56 % | SIHUAN PHARM (00460): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDER | ||
CHINA SHINEWAY PHARMACEUTICAL GROUP | 1,150 | +1,77 % | China Shineway Pharmaceutical Group Limited goes ex dividend Monday | ||
CHINA RESOURCES PHARMACEUTICAL | 0,595 | +2,59 % | CHINARES PHARMA (03320): JOINT ANNOUNCEMENT CONTINUING CONNECTED TRANSACTIONS SUPPLY CHAIN MANAGEMENT SERVICES REVISION OF ANNUAL CAPS AND EXTENSION OF ... | ||
HANSOH PHARMACEUTICAL | 2,040 | +3,03 % | HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - LICENSING AGREEMENT WITH QYUNS | ||
YICHANG HEC CHANGJIANG PHARMACEUTICAL | - | - | HEC CJ PHARM (01558): 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | ||
KALBE FARMA | 0,075 | -1,97 % | Allocating IDR 1 trillion, KLBF to set buyback of 625 million shares: PT Kalbe Farma Tbk (KLBF) is allocating ... |